Antenatal screening for Down's syndrome: where are we and where next?

Lancet. 1998 Aug 1;352(9125):336-7. doi: 10.1016/S0140-6736(98)22031-9.
No abstract available

Publication types

  • Comment

MeSH terms

  • Amniocentesis
  • Biomarkers / blood
  • Chorionic Gonadotropin / blood
  • Chromosomes, Human, Pair 21 / genetics
  • Down Syndrome / diagnosis*
  • Down Syndrome / diagnostic imaging
  • Down Syndrome / genetics
  • Down Syndrome / prevention & control
  • Estriol / blood
  • Female
  • Fetal Diseases / diagnosis*
  • Fetal Diseases / diagnostic imaging
  • Fetal Diseases / genetics
  • Fetal Diseases / prevention & control
  • Genetic Markers / genetics
  • Genetic Testing
  • Humans
  • Inhibins / blood
  • Mass Screening
  • Maternal Age
  • Polymerase Chain Reaction
  • Pregnancy / blood
  • Pregnancy, High-Risk
  • Prenatal Diagnosis*
  • Ultrasonography, Prenatal
  • alpha-Fetoproteins / analysis

Substances

  • Biomarkers
  • Chorionic Gonadotropin
  • Genetic Markers
  • alpha-Fetoproteins
  • Inhibins
  • Estriol